Table 2. Results of univariate analysis for different regorafenib-related off-target effects on patients’ outcome in terms of DCR, mPFS and mOS.
DCR | p | PFS (months) | HR (95% CI) | p | OS (months) | HR (95% CI) | p | |
---|---|---|---|---|---|---|---|---|
HFSR | ||||||||
Grade ≥2: 41 (28%) | 47% | 0.0269 | 3.2 | 0.73 (0.51–1.04) | 0.10 | 6.59 | 0.80 (0.52–1.25) | 0.35 |
Grade 0–1: 103 (72%) | 25% | 2.5 | 5.96 | |||||
SKIN RASH | ||||||||
Grade ≥2: 38 (26%) | 55% | 0.00387 | 3.67 | 0.60 (0.42–0.86) | 0.0096 | 10.36 | 0.54 (0.36–0.86) | 0.0085 |
Grade 0–1: 106 (74%) | 21% | 2.68 | 5.04 | |||||
HYPERTENSION | ||||||||
Grade ≥2: 29 (20%) | 48% | 0.0526 | 4.32 | 0.61 (0.41–0.89) | 0.0197 | 7.18 | 0.71 (0.45–1.13) | 0.188 |
Grade 0–1: 115 (80%) | 27% | 2.65 | 5.04 | |||||
FATIGUE Yes/No | ||||||||
Grade ≥2: 65 (45%) | 32% | 1.0000 | 2.85 | 0.93 (0.66–1.32) | 0.716 | 7.18 | 0.76 (0.50–1.14) | 0.195 |
Grade 0–1: 79 (55%) | 30% | 2.68 | 6.03 | |||||
AST/ALT ELEVATION | ||||||||
Grade ≥2: 18 (12%) | 43% | 0.29 | 3.01 | 1.11 (0.65–1.89) | 0.68 | 4.16 | 1.60 (0.83–3.10) | 0.08 |
Grade 0–1: 126 (88%) | 29% | 2.78 | 6.32 | |||||
BILIRUBIN INCREASE | ||||||||
Grade ≥2: 15 (10%) | 23% | 0.75 | 2.82 | 1.42 (0.75–2.69) | 0.20 | 8.98 | 1.21 (0.63–2.33) | 0.52 |
Grade 0–1: 129 (90%) | 32% | 2.78 | 6.03 | |||||
HYPOTHYROIDISM | ||||||||
Grade ≥2: 13 (9%) | 71% | 0.03 | 7.96 | 0.56 (0.34–0.93) | 0.0635 | NR | 0.10 (0.05–0.19) | 0.0042 |
Grade 0–1: 131 (91%) | 28% | 2.75 | 5.83 | |||||
DIARRHEA | ||||||||
Grade ≥2: 21 (15%) | 53% | 0.0489 | 5.11 | 0.54 (0.36–0.81) | 0.0130 | 11.41 | 0.53 (0.32–0.88) | 0.0440 |
Grade 0-1: 123 (85%) | 27% | 2.65 | 5.27 |
DCR = disease control rate, PFS = progression-free survival, HR = Hazard ratio, CI = confidence interval, OS = overall survival, HFSR = hand and foot skin reaction, AST = Aspartate Aminotransferase, ALT = alanine aminotransferase.